BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28414323)

  • 41. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Anand M; Lai R; Gelebart P
    Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.
    Uchihara Y; Ueda F; Tago K; Nakazawa Y; Ohe T; Mashino T; Yokota S; Kasahara T; Tamura H; Funakoshi-Tago M
    PLoS One; 2017; 12(8):e0183003. PubMed ID: 28806414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.
    Spaccarotella E; Pellegrino E; Ferracin M; Ferreri C; Cuccuru G; Liu C; Iqbal J; Cantarella D; Taulli R; Provero P; Di Cunto F; Medico E; Negrini M; Chan WC; Inghirami G; Piva R
    Haematologica; 2014 Jan; 99(1):116-24. PubMed ID: 23975180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma.
    Dalton RR; Rassidakis GZ; Atwell C; Wang S; Oyarzo MP; Medeiros LJ
    Hum Pathol; 2005 Jul; 36(7):806-11. PubMed ID: 16084951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.
    Garces de Los Fayos Alonso I; Zujo L; Wiest I; Kodajova P; Timelthaler G; Edtmayer S; Zrimšek M; Kollmann S; Giordano C; Kothmayer M; Neubauer HA; Dey S; Schlederer M; Schmalzbauer BS; Limberger T; Probst C; Pusch O; Högler S; Tangermann S; Merkel O; Schiefer AI; Kornauth C; Prutsch N; Zimmerman M; Abraham B; Anagnostopoulos J; Quintanilla-Martinez L; Mathas S; Wolf P; Stoiber D; Staber PB; Egger G; Klapper W; Woessmann W; Look TA; Gunning P; Turner SD; Moriggl R; Lagger S; Kenner L
    Mol Cancer; 2022 Aug; 21(1):172. PubMed ID: 36045346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
    Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
    J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.
    Toda T; Watanabe M; Kawato J; Kadin ME; Higashihara M; Kunisada T; Umezawa K; Horie R
    Br J Haematol; 2015 Sep; 170(6):837-46. PubMed ID: 26105086
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
    Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
    Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
    Ouyang T; Bai RY; Bassermann F; von Klitzing C; Klumpen S; Miething C; Morris SW; Peschel C; Duyster J
    J Biol Chem; 2003 Aug; 278(32):30028-36. PubMed ID: 12748172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
    Han Y; Amin HM; Franko B; Frantz C; Shi X; Lai R
    Blood; 2006 Oct; 108(8):2796-803. PubMed ID: 16825495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
    Ceccon M; Merlo MEB; Mologni L; Poggio T; Varesio LM; Menotti M; Bombelli S; Rigolio R; Manazza AD; Di Giacomo F; Ambrogio C; Giudici G; Casati C; Mastini C; Compagno M; Turner SD; Gambacorti-Passerini C; Chiarle R; Voena C
    Oncogene; 2016 Jul; 35(29):3854-3865. PubMed ID: 26657151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.
    Cho-Vega JH; Rassidakis GZ; Amin HM; Tsioli P; Spurgers K; Remache YK; Vega F; Goy AH; Gilles F; Medeiros LJ
    Leukemia; 2004 Nov; 18(11):1872-8. PubMed ID: 15385932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
    Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
    Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
    Marzec M; Kasprzycka M; Ptasznik A; Wlodarski P; Zhang Q; Odum N; Wasik MA
    Lab Invest; 2005 Dec; 85(12):1544-54. PubMed ID: 16170336
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.
    Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA
    Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma.
    Hegazy SA; Alshareef A; Gelebart P; Anand M; Armanious H; Ingham RJ; Lai R
    Cell Signal; 2013 Jan; 25(1):295-307. PubMed ID: 23022960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IGF1 regulates PKM2 function through Akt phosphorylation.
    Salani B; Ravera S; Amaro A; Salis A; Passalacqua M; Millo E; Damonte G; Marini C; Pfeffer U; Sambuceti G; Cordera R; Maggi D
    Cell Cycle; 2015; 14(10):1559-67. PubMed ID: 25790097
    [TBL] [Abstract][Full Text] [Related]  

  • 60. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
    Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K
    Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.